-
Send to Friends (0)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Checklist of Responsibilities for the Scientific Editor of This Article
Publishing Process of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6493)
All Articles published online
|
Publishing Process of This Article
|
Jun 7, 2020 (publication date) through Jun 4, 2023
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Saleh SA, Salama MM, Alhusseini MM, Mohamed GA. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. World J Gastroenterol 2020; 26(21): 2864-2876 [PMID: 32550761 DOI: 10.3748/wjg.v26.i21.2864] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v26/i21/2864.htm |
| Number | Citing Articles |
| 1 |
Alessia Virzì, Victor Gonzalez-Motos, Simona Tripon, Thomas F. Baumert, Joachim Lupberger. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. Journal of Clinical Medicine 2021; 10(5): 977 doi: 10.3390/jcm10050977
|
| 2 |
Takanori Suzuki, Kentaro Matsuura, Yoshihito Nagura, Shintaro Ogawa, Kei Fujiwara, Shunsuke Nojiri, Takehisa Watanabe, Hiromi Kataoka, Yasuhito Tanaka. Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents. Hepatology Research 2022; 52(11): 919 doi: 10.1111/hepr.13823
|
| 3 |
Manal Sabry Mohamed, Sameh Ghaly, Karim Hamed Azmy, Ghada Abdelrahman Mohamed. Assessment of interleukin 32 as a novel biomarker for non-alcoholic fatty liver disease. Egyptian Liver Journal 2022; 12(1) doi: 10.1186/s43066-022-00189-w
|
| 4 |
Kawin Tangvoraphonkchai, Tanita Suttichaimongkol, Churairat Kularbkaew, Prakasit Sangaimwibool, Wattana Sukeepaisarnjaroen. Application of Mac-2 binding protein glycosylation isomer as a non-invasive biomarker for probing liver disease. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-10744-5
|
| 5 |
Chen-Hua Liu, Chun-Jen Liu, Tung-Hung Su, Shang-Chin Huang, Tai-Chung Tseng, Jo-Hsuan Wu, Pei-Jer Chen, Jia-Horng Kao. Serum Mac-2 Binding Protein Glycosylation Isomer to Predict the Severity of Hepatic Fibrosis in Patients with Hepatitis C Virus Infection. Diagnostics 2022; 12(11): 2650 doi: 10.3390/diagnostics12112650
|
| 6 |
Zhiyang Chen, Yichen Ma, Jingyao Cai, Mei Sun, Ling Zeng, Fengxi Wu, Yiru Zhang, Min Hu. Serum biomarkers for liver fibrosis. Clinica Chimica Acta 2022; 537: 16 doi: 10.1016/j.cca.2022.09.022
|
| 7 |
Shereen Abou Bakr Saleh, Khaled Mohamed Abdelwahab, Asmaa Mady Mady, Ghada Abdelrahman Mohamed. The impact of achieving a sustained virological response with direct-acting antivirals on serum autotaxin levels in chronic hepatitis C patients. Egyptian Liver Journal 2020; 10(1) doi: 10.1186/s43066-020-00060-w
|